CN112888690A - 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 - Google Patents
取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 Download PDFInfo
- Publication number
- CN112888690A CN112888690A CN201980053055.XA CN201980053055A CN112888690A CN 112888690 A CN112888690 A CN 112888690A CN 201980053055 A CN201980053055 A CN 201980053055A CN 112888690 A CN112888690 A CN 112888690A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- cancer
- crystal
- maleate salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本申请属于药物化学领域,涉及取代的吡咯并嘧啶类CDK抑制剂的盐,具体涉及化合物7‑环戊基‑6‑N,N‑二甲氨基甲酰基‑N‑(5‑(1,2,3,6‑4H‑吡啶‑4‑基)吡啶‑2‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑2‑胺马来酸盐(式II化合物)、式II化合物的晶型、其制备方法、药物组合物,还涉及该化合物盐及其药物组合物在制备治疗与CDK4和/或CDK6抑制作用相关的疾病的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018110683525 | 2018-09-13 | ||
CN201811068352 | 2018-09-13 | ||
PCT/CN2019/105583 WO2020052627A1 (zh) | 2018-09-13 | 2019-09-12 | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112888690A true CN112888690A (zh) | 2021-06-01 |
CN112888690B CN112888690B (zh) | 2022-04-12 |
Family
ID=69776755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980053055.XA Active CN112888690B (zh) | 2018-09-13 | 2019-09-12 | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2022500458A (zh) |
CN (1) | CN112888690B (zh) |
AU (1) | AU2019338032A1 (zh) |
CA (1) | CA3112496A1 (zh) |
WO (1) | WO2020052627A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179793A1 (zh) * | 2022-03-25 | 2023-09-28 | 成都嘉葆药银医药科技有限公司 | 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017162215A1 (zh) * | 2016-03-25 | 2017-09-28 | 正大天晴药业集团股份有限公司 | 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20135785B (en) * | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
CN105294737B (zh) * | 2014-07-26 | 2019-02-12 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
EP3231805B1 (en) * | 2014-12-12 | 2020-03-04 | Crystal Pharmatech Co. Ltd. | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt |
-
2019
- 2019-09-12 AU AU2019338032A patent/AU2019338032A1/en not_active Abandoned
- 2019-09-12 WO PCT/CN2019/105583 patent/WO2020052627A1/zh active Application Filing
- 2019-09-12 CN CN201980053055.XA patent/CN112888690B/zh active Active
- 2019-09-12 JP JP2021514429A patent/JP2022500458A/ja active Pending
- 2019-09-12 CA CA3112496A patent/CA3112496A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017162215A1 (zh) * | 2016-03-25 | 2017-09-28 | 正大天晴药业集团股份有限公司 | 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112888690B (zh) | 2022-04-12 |
WO2020052627A1 (zh) | 2020-03-19 |
CA3112496A1 (en) | 2020-03-19 |
JP2022500458A (ja) | 2022-01-04 |
AU2019338032A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10611762B2 (en) | Crystalline forms of a FGFR inhibitor and processes for preparing the same | |
US8884013B2 (en) | Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof | |
WO2017219948A1 (en) | Crystalline forms of triazolopyrimidine compound | |
US11040979B2 (en) | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR | |
US20180291005A1 (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
CN110759908B (zh) | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 | |
WO2021238817A1 (zh) | 大环jak抑制剂及其应用 | |
US12084431B2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
US20230331703A1 (en) | Egfr inhibitors | |
EP3812386A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
CN112888690B (zh) | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 | |
CN111205290B (zh) | 一种jak激酶抑制剂的结晶形式及其制备方法 | |
CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
CN109476634B (zh) | 喹唑啉衍生物的盐的晶体 | |
AU2023236231A1 (en) | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof | |
US11111234B2 (en) | Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof | |
AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
WO2011145548A1 (ja) | ジ(アリールアミノ)アリール化合物の結晶 | |
CN110903291B (zh) | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 | |
CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 | |
US11160806B2 (en) | Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it | |
WO2023116895A1 (zh) | Kras抑制剂的多晶型物及其制备方法和用途 | |
KR20230026384A (ko) | 화합물의 결정 형태 | |
CN117769560A (zh) | Egfr抑制剂的盐、晶型及其组合物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40050133 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |